Archived Monthly Oncology Tumor Boards: Use of Checkpoint Inhibitors for Treatment of Metastatic Colorectal Cancer

The treatment of colorectal cancer continues to evolve. There have been advances in metastatic disease, with checkpoint inhibitors for dMMR/MSI-H disease becoming more prominent as a first-line or subsequent-line treatment option. Optimal treatment strategies can maximize benefits while minimizing harms, giving patients with metastatic colorectal cancer the best quality and quantity of life possible. It is difficult for clinicians to stay current with the evolving treatment options for colorectal cancer, and they can benefit from education about these  therapies.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Explain results of recent clinical trials of systemic therapies for patients with metastatic colorectal cancer.
  • Compare and contrast sequencing and selection decisions regarding checkpoint inhibitor therapy for metastatic colorectal cancer.
  • Review emerging systemic therapy options for metastatic colorectal cancer and how these new therapies may be incorporated into a treatment plan.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Coherus BioSciences
  • Exact Sciences
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Lilly
  • Novartis

This activity is supported by independent educational grants from:

  • Merck & Co., Inc.
  • Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

This educational activity is supported by medical education grants from:

  • Exelixis, Inc.
  • Karyopharm Therapeutics
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
02/22/2023
Course expires: 
02/22/2024
Cost:
$0.00
Part of: 
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care

Michael Overman, MD
The University of Texas MD Anderson Cancer Center

Kanwal P.S. Raghav, MD, MBBS
The University of Texas MD Anderson Cancer Center

Victoria Serpas Higbie, MD
The University of Texas MD Anderson Cancer Center
 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Victoria Serpas Higbie, MD

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Michael Overman, MD
Eisai Inc.: Consulting Fee
Gritstone: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
Merck & Co., Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Phanes: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

Kanwal P.S. Raghav, MBBS, MD
Bayer HealthCare: Consulting Fee; Scientific Advisor
Daiichi- Sankyo Co. Consulting Fee; Scientific Advisor
Eisai Inc.: Consulting Fee; Scientific Advisor
EMD Serono: Consulting Fee
Pfizer Inc.: Consulting Fee
SAGA Diagnostics: Consulting Fee
SeaGen: Consulting Fee; Scientific Advisor

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-23-018-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until February 22, 2024. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: I00053863; Approval #: 230000310

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing